Atilla, Below is the Sep 28, 2016 news release reference the MTA with Biogen. Where Biogen is in the testing process depends on when they started the assay and the start of the subsequent remeyelination testing. And also what the level of its complexity is, i.e. how many of their current M/S approved drugs and pipeline M/S drugs are they comparing 2-73 in compound with. Lets say they started in Dec giving them two months to set up the original testing. So, they have had 2-73 in their labs going on 6 months.
I believe they have seen some and even convincing proof of 2-73 efficacy alone or in tandem. But, they control the release of any info/data. And, I believe Vournatsos is working even wresling with his staff on the implications of the testing. This would not only be for M/S but for Biogen's current Alzheimers program. And you can believe there are proponents within his staff that are heavily invested technically in Aducanumab and the newly acquired BMS tau antibody drug.
So, the release of info IMHO is being held up by internal politics within Biogen. Depending on the strength of Vournatsos' position and his persuasiveness before the BOD, we will see patent, partnership and $ discussions. This well may take months, but could accelerate with Rett recruitment, patent announcement, or FDA Fast Track designation.
-------
NEW YORK, NY, September 28, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that it has signed a material transfer agreement with Biogen (Cambridge, MA) under which Biogen will test Anavex’s lead drug candidate, ANAVEX 2-73 in an oligodendrocyte precursor cell (OPC) differentiation assay. A satisfactory result from the OPC assay study may lead to an in vivo remyelination study using a chemical demyelination model.
“Battling demyelinating diseases such as multiple sclerosis requires an understanding of the processes that cause remyelination to fail. Remyelination of demyelinated axons is typically a function of oligodendrocyte precursor cells. These studies will examine the therapeutic role ANAVEX 2-73 may play in permitting remyelination in the brain,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
News 
Market Data 
Discover 
